fda shortage semaglutide Declares of Novo Nordisk's Wegovy, Ozempic Over fda semaglutide compounding enforcement november

Established thrombotic risk factors commonly present in semaglutide users include: Obesity (BMI 30 kg/m), which increases VTE risk 2-3 fold [13] Type 2 diabetes and insulin resistance Prolonged immobility or sedentary lifestyle History of previous blood clots Active cancer or recent cancer treatment Recent surgery, particularly orthopedic or abdominal procedures Smoking Certain medications, including estrogen-containing contraceptives or hormone replacement therapy Inherited thrombophilias (clotting disorders) Advanced age (risk increases after age 60) Pregnancy and postpartum period (note that semaglutide should be discontinued when pregnancy is recognized) Patients initiating semaglutide should undergo comprehensive baseline assessment including medical history review, with particular attention to prior thrombotic events and family history of clotting disorders

Those in high-risk groups should seek medical advice earlier if symptoms develop

It's always best to confirm coverage directly with your specific BCBS FEP plan

Weight Loss Benefits Weight loss is a significant benefit of both drugs, especially for patients with type 2 diabetes who often face challenges with obesity

The dosage you receive and the frequency of injections may vary according to your customized treatment plan

Track Progress: Celebrate small victories from regular dosing to clothing fitting better